CLVL.Y Stock Overview
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CLVL.Y from our risk checks.
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$9.75 |
| 52 Week High | AU$13.92 |
| 52 Week Low | AU$8.54 |
| Beta | 0.74 |
| 1 Month Change | 6.38% |
| 3 Month Change | -5.80% |
| 1 Year Change | -28.65% |
| 3 Year Change | -58.13% |
| 5 Year Change | -37.30% |
| Change since IPO | 48.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLVL.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -4.2% | -3.7% |
| 1Y | -28.6% | -2.0% | 20.5% |
Return vs Industry: CLVL.Y underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: CLVL.Y underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| CLVL.Y volatility | |
|---|---|
| CLVL.Y Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLVL.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: CLVL.Y's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| CLVL.Y fundamental statistics | |
|---|---|
| Market cap | US$492.04m |
| Earnings (TTM) | US$19.36m |
| Revenue (TTM) | US$52.51m |
25.4x
P/E Ratio9.4x
P/S RatioIs CLVL.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLVL.Y income statement (TTM) | |
|---|---|
| Revenue | AU$81.76m |
| Cost of Revenue | AU$6.70m |
| Gross Profit | AU$75.06m |
| Other Expenses | AU$44.90m |
| Earnings | AU$30.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 91.80% |
| Net Profit Margin | 36.88% |
| Debt/Equity Ratio | 0% |
How did CLVL.Y perform over the long term?
See historical performance and comparison